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Abstract
The relat ionship between the immune system, 
estrogen deficiency and bone loss is an intriguing 
and, as yet, unexplained challenge of the past two 
decades. Here we summarize the evidence that links 
immune cells, inflammation, cytokine production and 
osteoclast formation and activity with particular regard 
to humans.
© 2011 Baishideng. All rights reserved.
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INTRODUCTION
The bone, hematopoietic and immune systems are in deep 
physical contact and share several common pathways. 
Inflammatory disease characterized by systemic and local 
bone loss is an interesting field with which to explore the 
relationship between activation of  the immune system and 
bone remodelling. In the last few years, investigators have 
shed light on this topic and T cells have been recognized 
as key regulators of  osteoclast (OC) and osteoblast (OB)[1] 
formation and activity in different pathological conditions, 
such as osteoporosis[2], rheumatoid arthritis (RA)[3], bone 
metastasis[4,5] and periodontitis[6,7].
Estrogen deprivation induces bone loss. At the same 
time estrogens are well known regulators of  the immune 
system and T cell functions[8,9]. Thus the immune system 
can be suggested as a key interface between estrogen de-
privation and bone metabolism. 
The role of  the immune system in bone resorption is 
still controversial: studies on humans are few and the ma-
jority of  the data have been derived from animal models 
and cellular cultures. This review aims to summarize the 
evidences linking immune activation and bone loss with 
particular attention to humans. 
Cytokines and OC formation
The Receptor Activator of  NFkB Ligand (RANKL) and 
Macrophage Colony Stimulating Factor (M-CSF) are 
produced by bone marrow stromal cells[10], OBs[11] and 
activated T cells[2,12]. The co-stimulation by RANKL and 
M-CSF is essential for the differentiation of  monocytes 
into OCs[13-15]. 
M-CSF induces the proliferation of  OC precursors, 
differentiation and fusion of  more mature OCs and in-
creases the survival of  mature OCs. RANKL promotes 
the differentiation of  OC precursors into fully mature 
multinucleated OCs and stimulates the capacity of  ma-
ture OCs to resorb bone. 
RANKL is a member of  the TNF superfamily, 
present both as a transmembrane and in secreted form. 
It binds to its physiological receptor RANK expressed 
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on the surface of  OC lineage cells. Its action is opposed 
by osteoprotegerin (OPG), a neutralizing soluble decoy 
receptor, produced by marrow stromal cells and OBs[13]. 
Estrogen deficiency induces the imbalance between 
RANKL and OPG; this phenomenon is important in 
the genesis of  post-menopausal bone loss[15,16]. 
Some studies questioned the central role of  RANKL 
and suggested the hypothesis that activated T cells could 
induce osteoclastogenesis by an independent mechanism 
since saturating concentrations of  OPG failed to neu-
tralize more than 30% of  OC formation induced by acti-
vated T cells[17]. Rifas and Weitzmann discovered a novel 
cytokine called Secreted Osteoclastogenic Factor of  
Activated T cells (SOFAT) in activated T cell medium. 
This cytokine induces both osteoblastic IL-6 production 
and functional OC formation in the absence of  OBs or 
RANKL, insensitive to the effects of  OPG. 
The demonstration that SOFAT is a potent inducer 
of  IL-6 production by OBs suggests that it could play 
a significant role in the local inflammatory response 
and also could exacerbate bone destruction in rheuma-
toid arthritis indirectly through multiple IL-6-mediated 
events[18]. 
Estrogen deficiency induces bone loss through a 
complex modification of  cytokine production balance. 
Primarily, researchers observed increased TNFα produc-
tion by T cells both in ovariectomized mice[19] and post-
menopausal women[2,20]. TNFα enhances OC formation 
by up-regulating stromal cell production of  RANKL 
and M-CSF and by increasing the responsiveness of  OC 
precursors to RANKL[5,21]. Besides, other studies showed 
a key role of  T cell-produced TNFα in rheumatoid arthri-
tis[3,22], multiple myeloma[23,6] and bone metastasis[4,5]. The 
effect of  TNFα on osteoclastogenesis is up-regulated by 
IL-1[24]; this cytokine production increases after meno-
pause[20,25], enhancing RANKL expression by bone mar-
row stromal cells and directly promoting OC differen-
tiation. In fact, treatment with IL-1 receptor antagonist 
decreases OC formation and bone resorption in ovariec-
tomized mice[26,27], whereas the blockade of  both TNFα 
and IL-1 reduce bone resorption in post-menopausal 
osteoporosis[28].
IFNγ role in osteoclastogenesis has been hard to 
defi ne: this cytokine has an anti osteoclastogenic effect 
in vitro[29] and in vivo in nude mice models[30,31]. Studies 
in humans indicate an increased level of  IFNγ during 
estrogen deficiency[32,33], in leprosy and rheumatoid ar-
thritis with bone erosions[34,35]. Moreover, data from ran-
domized  controlled trials have shown that IFNγ does 
not prevent bone loss in patients with RA[36,37] nor the 
bone wasting effect of  cyclosporin A[1]. These data are 
explained by the finding that IFNγ influences OC for-
mation both via direct and indirect effects[32]. It directly 
blocks OC formation targeting maturing OC[38] and also 
induces antigen presentation and thus T cell activation. 
When IFNγ levels are increased in vivo, activated T cells 
secrete pro-osteoclastogenic factors and this activity off-
sets the anti-osteoclastogenic effect of  IFNγ[39].
T cells also produce interleukin-7 (IL-7), a cytokine 
able to enhance B and T cell number and reactivity to 
antigenic stimulus[40,41]. Some studies have demonstrated 
that IL-7 promotes osteoclastogenesis by up-regulating 
T cell-derived osteoclastogenic cytokines including 
RANKL[42-44] and that the production is up-regulated 
by estrogen defi ciency. In vivo IL-7 blockade is proven 
to suppress T cell expansion and TNFα and IFNγ pro-
duction, preventing bone loss due to estrogen depriva-
tion[45,46]. In healthy humans, the expression of  IL-7 
receptors on T lymphocytes is strictly related to their 
ability to induce OC formation from peripheral blood 
Figure 1  Multiple cytokines have a role in the regulation of OC formation and activity. Their complex interactions are important in explaining bone loss after 
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bone marrow but also as a potentially abundant source 
of  pre-OCs that can be recruited into bone or joint tis-
sue in response to reparative or pathological signals. On 
this basis OCs can be considered as immune cells at-
tracted in bone by stimulatory cytokines, expressed on 
accessory cells and undergoing specific differentiation.
For a long time, osteoimmunology focused on OC 
regulation by T cells. Recently investigators have paid 
attention to the feedback action of  OCs on T cells. 
Kiesel et al. observed that OCs are able to present anti-
genic peptides to T cells and induce FoxP3 expression 
in CD8+ T cells, thus originating Treg CD8+ cells able 
to regulate inappropriate activation of  the immune re-
sponse[58]. 
Senthilkumar et al[59] suggest that the cellular respons-
es in cell-to-cell interactions between T cells and OCs 
are regulated through reciprocal CD137/CD137L and 
RANK/RANKL interactions. CD137 is a co-stimulatory 
member of  the TNF receptor induced by T cell recep-
tor activation, characterized by the ability to transduce 
signals in both directions, through the receptor and into 
the cell that expresses the ligand. Its ligand CD137L is 
expressed on APCs and OC precursors; in vitro CD137L 
ligation suppresses osteoclastogenesis through the inhi-
bition of  multi-nucleation. On the other hand, RANKL 
expressed on T cells bind to RANK on OCs, producing 
a reverse signal in T cells able to enhance apoptosis. 
Periprosthetic osteolysis is another important re-
search field to understand the reciprocal interactions of  
OC and T cells. Periprosthetic osteolysis patients show 
T cell-dependent osteoclastogenesis in PBMC cultures; 
in fact the process was inhibited by RANK-Fc and T cell 
depletion[60]. In periprosthetic tissues local CD8+ T cells 
showed a regulatory phenotype, expressing CD25 and 
FoxP3, while CD4+ T cells did not express activation 
markers. These data suggest that in an early stage T cells 
promote osteoclastogenesis, while subsequently OCs ac-
tivate FoxP3/CD8+ T cells which inhibit CD4+ effector 
T cells. 
Estrogen loss and immune system
The role of  estrogen in the regulation of  immune func-
tion has been demonstrated in animals and humans: im-
mune cells are more responsive to antigenic stimulus in 
hormone replacement therapy users than non-users[61]. 
Our group demonstrated that T cells from post-
menopausal women show blunt reaction to immune 
stimulation in respect to pre-menopausal healthy women. 
At baseline, T cells are more active than in healthy post- 
and pre-menopausal controls: this implies their greater 
ability to produce RANKL and TNFα, thus inducing 
OC formation and activity[2]. We have also demonstrated 
that OC formation is abolished in T cell-depleted PBMC 
cultures and this phenomenon is reversed only by the 
addition of  M-CSF and RANKL in cultures. 
Grcevic et al[62] suggested a probable role for resting 
T cells in blunting OC formation; CD4+ and CD8+ T 
cell-depleted mice have an increased OC formation rate 
since OPG production is suppressed. T cell-deficient 
mononuclear cells (PBMC)[47]. A comprehensive sum-
mary of  these pathways can be found in Figure 1.
Inflammation and bone loss
Both acute and chronic inflammatory diseases in the 
periosseous tissues are well known to cause bone dam-
age as inflammation increases the OC number and activ-
ity. The activation of  T cells in autoimmunity or during 
infection increases RANKL production and promote 
osteoclastogenesis. The process can be reverted by the 
administration of  OPG in several pathological condi-
tions such as RA and periodontitis[48]. Particularly in 
autoimmune arthritis, T cell subsets have been examined 
and Th17 cells, a specialized inflammatory subset, have 
been identified as responsible for osteoclastogenesis 
regulation. An inflammatory milieu induces naïve T cells 
to differentiate into Th17, capable to produce RANKL, 
TNFα and IL-17, a cytokine that increases RANKL ex-
pression by OBs[49].
Researchers recently began to investigate a possible 
direct role of  dendritic cells (DC) in inflammation-
related bone damage. DCs are known for their role of  
antigen presenting cells (APCs) and do not appear to 
play a role in bone homeostasis in non-pathological con-
ditions, but some data suggest that DC could act as OC 
precursors in an inflammatory milieu, transforming into 
DC-derived-OC according to phenotypic and functional 
characterization studies. Moreover, DCs modulate T cell 
activity through RANK/RANKL pathway and other 
cytokines associated with osteoclastogenesis[50-52]. There 
is a lack of  definitive evidence about the physiological 
relevance of  this phenomenon in vivo but DCs could act 
as an osteo-immune interface, contributing to bone loss 
in inflammatory diseases.
On the other hand investigators have focused on the 
role of  B-lymphocytes in periodontal inflammation. The 
host immune response is partly responsible for the bone 
destruction in cases of  periodontitis and the RANK/
RANK/OPG signalling axis is important both in bone 
and immune system communication. Data suggest that 
B-lymphocyte involvement in the adaptive immune re-
sponse contributes to bone resorption by up-regulating 
of  RANKL expression through Toll-like receptor path-
ways. These data align with the known ability of  T cells 
to produce RANKL in the presence of  immune stimulus 
and to increase osteoclastogenesis[53]. 
Other studies focused on psoriatic arthritis, a chronic 
inflammatory disease characterized by joint erosions 
mediated by OCs. These OCs seem to derive from 
CD14+CD16+ circulating monocytes, present at higher 
level in patients than in healthy controls when exposed 
to OC-promoting microenvironment (M-CSF and 
RANKL). OCs do not derive from this population in 
healthy controls; thus CD16 can be considered a marker 
of  OC precursors in arthritis[54]. 
OC modulates T cell activity 
OC precursors circulate within the mononuclear fraction 
of  peripheral blood[2,4,55-57]. This population acts not only 
as a reservoir for replenishing the pre-OC pool in the 
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mice show an increased number of  OC in basal condi-
tions and a reduced bone density when compared to 
controls[42].
Estrogen withdrawal up-regulates TNFα produc-
tion by T cells through a complex pathway involving the 
thymus and bone marrow. In the bone marrow, ovari-
ectomy promotes T cell activation by increasing antigen 
presentation by macrophages and DCs[33,63]. Several stud-
ies showed the central role of  T cells-produced TNF in 
bone loss induced by estrogen deficiency; in the murine 
model ovariectomy increases the number of  bone mar-
row T cell-producing TNF[19,64,65]. In fact, ovariectomy 
stimulates the expression of  the gene encoding Class 
II TransActivator (CIITA), a transcriptional coactiva-
tor acting on the MHCII promoter, with the final effect 
of  up-regulation of  expression of  MHCII on macro-
phages[33,66,67]. This process proved essential since data 
show that ovariectomy induces rapid bone loss in wild 
type (wt) mice but failed to do so in TNFα-deficient 
[TNFα (-/-)] mice and in T cell-deficient nude mice. 
Bone loss was restored by adoptive transfer of  wt T cells 
but not by reconstitution with T cells from TNFα (-/-) 
mice[19], the bone-wasting effect of  TNFα is mediated 
by the p55 TNFα receptor. In fact, ovariectomy caused 
bone loss in wt mice and in mice lacking p75 TNFα re-
ceptor but failed to do so in mice lacking the p55 TNFα 
receptor[19].
Moreover, RANKL-expression on lymphocytes and 
marrow stromal cells is significantly elevated during es-
trogen deficiency in humans and correlates directly with 
increases in bone resorption markers and inversely with 
serum estrogen levels[16].
These data demonstrate the causal relationship be-
tween estrogen deprivation, T cell activation with in-
creased production of  cytokines, and bone resorption.
Estrogen withdrawal has effects on the B cell com-
partment as well. In ovariectomized mice B220+ IgM- 
population expands and can differentiate into OC[68-70]. 
Activated B cells over-express RANKL, contributing to 
bone resorption[71].  
CONCLUSION
Bone is a dynamic tissue that is constantly formed and 
resorbed; bone turnover is due to continuous and cyclic 
bone resorption followed by apposition. These processes 
are due to the coordinated actions of  OC and OB. The 
action of  these two cell types is regulated by paracrine 
and endocrine factors. In physiological conditions, OB 
and OC activity is coupled so that the amount of  resorp-
tion is equal to the amount of  formation. However, in 
pathological conditions or during senescence, resorption 
is higher than formation, leading to bone loss. OC and 
OB formation, as well as the coupling between these two 
cell types, are mediated mainly through cytokines. 
Cytokines have pleiotropic functions and regulate 
several organs and systems. In the last decade several 
investigators have paid attention to the relationship be-
tween estrogen withdrawal, cytokines production, the 
immune system and skeleton. Today the majority of  the 
data have been obtained in animal models but in recent 
years, new evidence has been accumulated in humans 
towards a profound link between estrogen deprivation, 
immune system deregulation and bone loss. If  this rela-
tionship is confirmed by future work, postmenopausal 
osteoporosis should be regarded as an inflammatory 
disorder sustained by a chronic mild decrease in T cell 
tolerance.
The relationship between the immune system and 
bone is complex and depends upon cytokine production 
and cell to cell contacts. T cells and OCs appear to be 
the main players in the mechanisms of  bone loss. Future 
studies are needed to fully understand these relationships 
in humans.
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